Bayer’s pharmaceutical division is poised for another year of resilience, with its key growth drivers, Nubeqa and Kerendia, exceeding expectations. Both drugs are projected to maintain their upward trajectory through 2026, bolstering Bayer’s long-term outlook. However, this positive momentum is unlikely to translate into overall growth for the company’s pharma sector in the near term, as it faces significant headwinds from two major products, Xarelto and Eylea, which are experiencing declines. The juxtaposition of strong performance from Nubeqa and Kerendia against the backdrop of Xarelto and Eylea’s contraction underscores the challenges Bayer must navigate. As the company prepares for a transitional year, stakeholders in regulatory, QA/QC, CMC, sourcing, and portfolio management will need to closely monitor these dynamics to understand their implications for future strategies and market positioning.
Start your 7-day trial and see what the database can do →
